Abstract:The emergence of multidrug resistance (MDR) in malignant tumors is one of the major threats encountered currently by many chemotherapeutic agents. Among the various mechanisms involved in drug resistance, P-glycoprotein (P-gp, ABCB1), a member of the ABC transporter family that significantly increases the efflux of various anticancer drugs from tumor cells, and the metabolic enzyme CYP1B1 are widely considered to be two critical targets in overcoming MDR. Unfortunately, no MDR modulator has been approved by the FDA to date. In this study, based on pharmacophore hybridization, bioisosteric and fragment-growing strategies, we designed and synthesized 11 novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors. Among them, the preferred compound A10 exhibited the best MDR reversal activity (IC 50 = 0.25 μM, RF = 44.4) in SW620/AD300 cells, being comparable to one of the most potent third P-gp inhibitor WK-X-34. In parallel, this dual ABCB1/CYP1B1 inhibitory effect drives compound A10 to exhibit a prominent drug resistance reversal activity to doxorubicin (IC 50 = 4.7 μM, RF = 13.7) in ABCB1/CYP1B1-overexpressing DOX-SW620/AD300-1B1 resistant cells, which is more potent than that of the CYP1B1 inhibitor ANF. Furthermore, although compound A2 possessed moderate ABCB1/CYP1B1 inhibitory activities, it showed considerable antiproliferative activity towards drug-resistant SW620/AD300 and MKN45-DDP-R cells, which may be related to the increase of PUMA expression to promote the apoptosis of the drug-resistant MKN45-DDP-R cells as confirmed by proteomics and western blot assay. These results indicated that tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates may provide a fundamental scaffold reference for further discovery of MDR reversal agents.

Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As P-glycoprotein-mediated Multidrug Resistance Inhibitors.

Discovery to Solve Multidrug Resistance: Design, Synthesis, and Biological Evaluation of Novel Agents

Design, Synthesis and Biological Evaluation of Novel Triazole-Core Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance

Design, Synthesis and Biological Evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide Derivatives As Novel P-glycoprotein Inhibitors Reversing Multidrug Resistance

Design and Synthesis of Tetrahydroisoquinoline Derivatives As Potential Multidrug Resistance Reversal Agents in Cancer.

Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1h)yl)ethyl)phenyl)quinazolin-4- Amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance

Design, Synthesis and Evaluation of a Novel Series of Inhibitors Reversing P‐glycoprotein‐mediated Multidrug Resistance

Design, Synthesis and Biological Evaluation of LBM-A5 Derivatives As Potent P-glycoprotein-mediated Multidrug Resistance Inhibitors.

Synthesis and Primary Evaluation of Quinoxalinone Derivatives As Potent Modulators of Multidrug Resistance

Designed P-glycoprotein Inhibitors with Triazol-Tetrahydroisoquinoline-core Increase Doxorubicin-Induced Mortality in Multidrug Resistant K562/A02 Cells.

1-Benzyl-1,2,3,4-tetrahydroisoquinoline Derivatives and Optically Pure Isomers As Novel Promising Multidrug Resistance (mdr) Reversing Agents

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance

Development of a Novel Quinoline Derivative As a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells

6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance.

Synthesis and Biological Evaluation of a Series of 6,7-Dimethoxy-1-(3,4- Dimethoxybenzyl)-2-substituted Tetrahydroisoquinoline Derivatives

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors